Last $26.79 USD
Change Today -0.15 / -0.56%
Volume 90.1K
FLDM On Other Exchanges
Symbol
Exchange
NASDAQ GS
Frankfurt
As of 8:10 PM 08/27/14 All times are local (Market data is delayed by at least 15 minutes).

fluidigm corp (FLDM) Snapshot

Open
$27.01
Previous Close
$26.94
Day High
$27.15
Day Low
$26.69
52 Week High
02/27/14 - $49.46
52 Week Low
08/28/13 - $19.87
Market Cap
754.7M
Average Volume 10 Days
175.1K
EPS TTM
$-1.08
Shares Outstanding
28.2M
EX-Date
--
P/E TM
--
Dividend
--
Dividend Yield
--
Current Stock Chart for FLUIDIGM CORP (FLDM)

Related News

No related news articles were found.

fluidigm corp (FLDM) Related Businessweek News

No Related Businessweek News Found

fluidigm corp (FLDM) Details

Fluidigm Corporation develops, manufactures, and sells microfluidic systems worldwide. It offers BioMark HD System that performs high-throughput and single-cell targeted gene expression analysis, single nucleotide polymorphism (SNP) genotyping, and digital polymerase chain reaction (PCR) using Fluidigm DELTAgene and SNPtype assays, other chemistries, and Fluidigm Dynamic Array and Digital Array integrated fluidic circuits (IFCs). The company also provides C1 Single-Cell Auto Prep System, which enables the isolation, processing, and profiling of individual cells for genomic analysis for applications comprising single-cell targeted gene expression, single-cell micro ribonucleic acid (RNA) analysis, single-cell messenger RNA analysis, and single-cell targeted DNA sequencing using the company’s C1 Single-Cell Auto Prep Array IFCs and C1 reagent kit. In addition, it offers EP1 System, which performs SNP genotyping using Fluidigm SNPtype assays or TagMan assays, as well as end-point digital PCR using TaqMan assays, and Fluidigm Dynamic Array and Digital Array IFCs; and Access Array System to enable PCR-based target enrichment, barcoding, and the tagging of targeted resequencing libraries. Further, the company provides Dynamic Array, Digital Array, C1 Single-Cell Auto Prep Array, and Access Array IFCs; DELTAgene and SNPtype assays; and Access Array Target-Specific primers. It serves academic institutions; clinical laboratories; and pharmaceutical, biotechnology, and agricultural biotechnology companies in single-cell genomics, applied genotyping, and sample preparation for targeted re sequencing markets. Fluidigm Corporation distributes its products through support organizations, distributors, or sales agents, as well as through its direct sales force. The company was formerly known as Mycometrix Corporation and changed its name to Fluidigm Corporation in April 2001. Fluidigm Corporation was founded in 1999 and is headquartered in South San Francisco, California.

325 Employees
Last Reported Date: 03/12/14
Founded in 1999

fluidigm corp (FLDM) Top Compensated Officers

Co-Founder, Chief Executive Officer, Presiden...
Total Annual Compensation: $425.0K
Chief Financial Officer and Principal Account...
Total Annual Compensation: $311.6K
Chief Operating Officer
Total Annual Compensation: $296.8K
Executive Vice President of Legal Affairs, Ge...
Total Annual Compensation: $312.0K
Executive Vice President of Research & Develo...
Total Annual Compensation: $308.1K
Compensation as of Fiscal Year 2013.

fluidigm corp (FLDM) Key Developments

Fluidigm Corporation Announces Unaudited Consolidated Earnings Results for the Second Quarter and Six Months Ended June 30, 2014; Revised Earnings Guidance for the Year 2014

Fluidigm Corporation announced unaudited consolidated earnings results for the second quarter and six months ended June 30, 2014. The company's total revenue for the second quarter of 2014 was $27.6 million, an increase of 58% from $17.5 million in the second quarter of 2013. Organic revenue (excluding revenue attributable to the DVS Sciences acquisition, comprised of the CyTOF(R) 2 system and proteomics analytical consumables) was $23.0 million, an increase of 32% over the same quarter in 2013. Net loss for the second quarter of 2014 was $12.7 million, compared to a net loss of $4.0 million in the second quarter of 2013. Non-GAAP net loss for the second quarter of 2014 was $1.7 million, compared with $1.7 million non-GAAP net loss for the second quarter of 2013. Loss from operations was $12,377,000 against $3,990,000 a year ago. Loss before income taxes was $13,810,000 against $4,031,000 a year ago. Net loss was $12,682,000 against $4,046,000 a year ago. For the six months period, the company's total revenue was $53,331,000 against $32,015,000 a year ago. Loss from operations was $28,956,000 against $9,057,000 a year ago. Loss before income taxes was $31,367,000 against $7,544,000 a year ago. Net loss was $28,096,000 or $1.03 per diluted share against $7,597,000 or $0.30 per diluted share a year ago. Net cash used in operating activities was $10,235,000 against $3,521,000 a year ago. Purchases of property and equipment were $4,563,000 against $912,000 a year ago. Net loss (non-GAAP) was $1,651,000 against $5,208,000 a year ago. The company has projected 2014 total revenue to be between $112 million to $118 million, an increase from the previous range of $111 million to $116 million. Organic revenue is projected to be between $94 million and $96 million, an increase of 32% to 35% over 2013. The company projects capital spending is expected to be between $11 million and $13 million. Interest expense is projected to be $5.3 million.

Fluidigm Corporation to Report Q2, 2014 Results on Jul 31, 2014

Fluidigm Corporation announced that they will report Q2, 2014 results at 5:00 PM, Eastern Standard Time on Jul 31, 2014

Fluidigm Corporation, Q2 2014 Earnings Call, Jul 31, 2014

Fluidigm Corporation, Q2 2014 Earnings Call, Jul 31, 2014

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
FLDM:US $26.79 USD -0.15

FLDM Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Biotage AB kr11.00 SEK 0.00
Luminex Corp $18.71 USD -0.41
NanoString Technologies Inc $11.41 USD +0.21
Pacific Biosciences of California Inc $5.38 USD +0.04
Sequenom Inc $3.83 USD -0.04
View Industry Companies
 

Industry Analysis

FLDM

Industry Average

Valuation FLDM Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 8.1x
Price/Book 4.7x
Price/Cash Flow NM Not Meaningful
TEV/Sales 5.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact FLUIDIGM CORP, please visit www.fluidigm.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.